Growth Hormone

Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag.  The FDA has pushed back approval of Pfizer's once-weekly prospect. Ascendis Pharma A/D (NASDAQ: ASND), after suffering its regulatory...

The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ages one and older with growth hormone deficiency (GHD) who weigh at least...

Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational new drug application multicenter, open-label trial will investigate the...

Here's a look at the top tickers trending on StockTwits.com. S&P 500 futures: Pre-market boost from calming tensions Investors woke up to news that Russian President Vladimir Putin has ordered troops who took part in a military exercise across central and western Russia back to their bases....